Summary
Rapid advances in research are delivering healthcare innovations or new methodologies that simply don’t fit in with current regulatory frameworks. As a result, their development, regulatory acceptance and evaluation is slow, and this in turn slows down patient access to them.
‘Regulatory sandboxes’ are flexible spaces where innovators and regulators can collaborate and explore the best way to regulate a new technology in such a way that end users are protected, while innovations are not held back by barriers that could be found in the existing regulatory framework. They are already used in sectors such as finance, but are still in their infancy in the health field.
The aim of the BRIDGE project is to develop a comprehensive set of recommendations for designing and implementing regulatory sandboxes in practice for health, including flexible, fit-for-purpose methodologies. One of the project’s first tasks will be to review existing regulatory sandbox mechanisms, along with relevant health policies and regulatory frameworks.
Today, regulatory sandboxes are usually established reactively, once a new technology already exists. BRIDGE plans to incorporate a proactive horizon scanning process to identify early on emerging trends and technologies that fall outside existing regulatory frameworks. This will allow regulators and innovators to anticipate and address challenges and opportunities relating to new technologies while they are still under development.
A core project outcome will be the MOSAIC (Modular Operational Sandbox for Healthcare Innovation and Compliance) model. As emerging healthcare technologies are both complex and diverse, any framework for regulatory sandboxes has to be flexible and adaptable enough to cope with a wide range of stakeholders, products, and regulatory requirements.
MOSAIC will feature a modular design with ‘bricks’ (which could be the resources, tools, processes or personnel needed for a specific sandbox) and a ‘module base’ (which sets out how to configure or assemble the bricks). By combining the right bricks with the module base, users can build functional modules that perform specific tasks within the regulatory sandbox, such as modelling, technology assessment, and clinical validation. The functional modules are then assembled to create a regulatory sandbox that is tailored to the specific technology.
The BRIDGE team will test its system via use cases drawn from fields which are already challenging the regulatory frameworks of today. These are expected to include advanced and biological therapies, technologies based on artificial intelligence (AI) and digital health, combination and hybrid technologies, emergency preparedness, and innovations in non-clinical testing during drug development.
The use case simulations will involve all key stakeholders, including developers, regulators, payers and patients, and will take the technologies selected through the entire process from pre-submission to sandbox exit. The use cases will help the project to improve its framework, which will be validated through consultation with expert panels including experts from regulatory and health technology assessment (HTA) authorities.
Ultimately, BRIDGE’s flexible, modular regulatory sandbox tool will provide Europe with innovative regulatory approaches that will allow novel technologies to be brought to patients faster.
Furthermore, by paving the way for a more anticipatory, adaptive and agile regulatory ecosystem in healthcare, BRIDGE’s work will contribute to key EU policies including the Competitiveness Compass, the pharmaceutical legislation, the AI act, and more.
Participants
Show participants on mapEFPIA including Vaccines Europe
- Astellas Pharma Europe BV, Leiden, Netherlands
- Biogen Idec Limited, Maidenhead, United Kingdom
- Csl Behring GMBH, Marburg, Germany
- Eli Lilly And Company, Indianapolis, United States
- Eli Lilly And Company LTD, Basingstoke, United Kingdom
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Federation Europeenne D'Associations Et D'Industries Pharmaceutiques, Bruxelles, Belgium
- Janssen Pharmaceutica Nv, Beerse, Belgium
- Lilly Deutschland GmbH, Bad Homburg, Germany
- MSD Europe Belgium, Brussels, Belgium
- Merck, Sharp & Dohme de España, S.A., Madrid, Spain
- Merck Healthcare Kgaa, Darmstadt, Germany
- Merck Kommanditgesellschaft Auf Aktien, Darmstadt, Germany
- Merck Serono Ltd., Feltham, United Kingdom
- Merck Sharp & Dohme Corp, Whitehouse Station Nj, United States
- Merckle GMBH, Blaubeuren, Germany
- Msd R&D Innovation Centre Limited, London, United Kingdom
- Novartis Pharma AG, Basel, Switzerland
- Novo Nordisk A/S, Bagsvaerd, Denmark
- Pfizer Healthcare Ireland Unlimited Company, Dublin, Ireland
- Pfizer Inc, New York City, United States
- Pfizer R&D UK Limited, Sandwich, United Kingdom
- Sanofi-Aventis Deutschland GMBH, Frankfurt Am Main, Germany
- Sanofi-Aventis Recherche & Developpement, Gentilly, France
- Sanofi Pasteur SA, Lyon, France
- Sanofi Winthrop Industrie, Gentilly, France
- Takeda Pharmaceuticals International AG, Glattpark, Switzerland
- Teva Pharmaceutical Industries Limited, Petach Tivka, Israel
Universities, research organisations, public bodies, non-profit groups
- Academisch Ziekenhuis Groningen, Groningen, Netherlands
- Bundesinstitut Fur Arzneimittel Und Medizinprodukte, Bonn, Germany
- Charite - Universitaetsmedizin Berlin, Berlin, Germany
- Euroscan International Network Ev, Koln, Germany
- Fundacion Publica Andaluza Progreso Y Salud M.P., Sevilla, Spain
- Technische Universitaet Dresden, Dresden, Germany
- Teknologian Tutkimuskeskus Vtt Oy, Espoo, Finland
- The European Association Medical Devices-Notified Bodies, Sprimont, Belgium
- The European Institute For Innovation Through Health Data, Oosterzele, Belgium
- The European Medicines Agency, Amsterdam, Netherlands
- Universite Bourgogne Europe, Dijon, France
- Vlaamse Instelling Voor Technologisch Onderzoek N.V., Mol, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
- Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh, Bonn, Germany
| Participants | |
|---|---|
| Name | EU funding in € |
| Academisch Ziekenhuis Groningen | 229 894 |
| Bundesinstitut Fur Arzneimittel Und Medizinprodukte | 402 613 |
| Charite - Universitaetsmedizin Berlin | 228 123 |
| Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh | 794 100 |
| Euroscan International Network Ev | 473 940 |
| Fundacion Publica Andaluza Progreso Y Salud M.P. | 270 313 |
| Technische Universitaet Dresden | 132 103 |
| Teknologian Tutkimuskeskus Vtt Oy | 519 007 |
| The European Association Medical Devices-Notified Bodies | 110 625 |
| The European Institute For Innovation Through Health Data | 584 063 |
| The European Medicines Agency | 197 595 |
| Universite Bourgogne Europe | 159 669 |
| Vlaamse Instelling Voor Technologisch Onderzoek N.V. | 1 097 773 |
| Total Cost | 5 199 818 |